Nasdaq-listed biotech company Windtree Therapeutics (WINT) announced it has signed a $500 million equity line of credit (ELOC ...

Windtree Therapeutics, recently made waves by announcing plans to allocate up to $700 million toward acquiring BNB.

WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NasdaqCM:WINT), a company with a current market capitalization of just $3 million and trading at $0.83 per share, announced Wednesday it has entered ...

WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late ...

Windtree Therapeutics shares are trading lower by 8.6% during Monday's session. The company announced it entered a $1M private placement. Don’t miss this list of 3 high-yield stocks—including ...

Windtree Therapeutics Announces Closing of $30.0 Million Public Offering August 19, 2021 at 12:58 p.m.

Windtree Therapeutics (NASDAQ:WINT) just reported results for the first quarter of 2024. Windtree Therapeutics reported earnings per share of -$20.91. The company did not report any revenue for ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the publication of findings from its Phase 2 SEISMiC B study on istaroxime in the Journal of Heart and Lung … ...

Windtree Therapeutics, Inc. announced the issuance of a new patent for istaroxime, an intravenous formulation aimed at treating acute heart failure (AHF), a condition responsible for 1.3 million ...

Windtree Therapeutics WINT just announced new preclinical data on the company’s lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions ...

Windtree Therapeutics out-licenses surfactant platform in a deal that could be worth nearly $80M Unlock URL Order Reprints Gift this Article ...